The development of viral vector vaccines against various pathogens for which conventional vaccination approaches are not applicable has been a priority for a number of years. One promising approach is the insertion of immunodominant conservative cytotoxic T-cell (CTL) epitopes into the genome of a viral vector, which then delivers these epitopes to target cells, inducing immunity. Many different viruses have been assessed as viral vectors for CTL-based vaccines, but only a few of them are clinically relevant, mainly because of safety issues and limited knowledge about their performance in humans. In this regard, the use of licensed cold-adapted live attenuated influenza vaccine (LAIV) viruses as a vector delivery system has clear advantages for CTL-based vector vaccines against other respiratory pathogens: LAIV is known to induce all arms of the adaptive immune system and is administered via nasal spray, and its production process is relatively easy and inexpensive. Here we present the first results of the use of an LAIV backbone for designing a CTL epitope-based vaccine against respiratory syncytial virus (RSV). The chimeric LAIV-RSV vaccine candidates were attenuated in mice and induced strong, fully functional CTL immunity in this animal model.
Live attenuated influenza vaccines (LAIVs) are considered as safe and effective tool to control influenza in different age groups, especially in young children. An important part of the LAIV safety evaluation is the detection of vaccine virus replication in the nasopharynx of the vaccinees, with special attention to a potential virus transmission to the unvaccinated close contacts. Conducting LAIV clinical trials in some geographical regions with year-round circulation of influenza viruses warrants the development of robust and reliable tools for differentiating vaccine viruses from wild-type influenza viruses in nasal pharyngeal wash (NPW) specimens of vaccinated subjects. Here we report the development of genotyping assay for the detection of wild-type and vaccine-type influenza virus genes in NPW specimens of young children immunized with Russian-backbone seasonal trivalent LAIV using Sanger sequencing from newly designed universal primers. The new primer set allowed amplification and sequencing of short fragments of viral genes in NPW specimens and appeared to be more sensitive than conventional real-time RT-PCR protocols routinely used for the detection and typing/subtyping of influenza virus in humans. Furthermore, the new assay is capable of defining the origin of wild-type influenza virus through BLAST search with the generated sequences of viral genes fragments.
1 August 2016 in Bulletin of Experimental Biology and Medicine
BACKGROUND: Transferrin receptor 1 (TfR1, CD71) is a multifunctional protein important for maintaining cellular iron homeostasis by binding to the main iron transporter transferrin (Tf). In addition to Tf, it can bind and transfer proteins, viruses, chemotherapeutic agents, and other biomolecules to the cell. Ferristatin II, a TfR1 degradation inducer, has previously been shown to inhibit SARS-CoV-2 infection in Vero cells; however, this agent cannot be used as a medicinal product, because its metabolism produces carcinogenic benzidine derivatives. AIM: To assess the antiviral activity of specific azo compounds (structural analogs of ferristatin II) to identify common structural patterns of compounds that are the most effective against SARS-CoV-2. The findings will be used to develop safer antiviral analogs of ferristatin II. METHODS: The paper investigates the antiviral activity of 15 compounds, including 5 de novo compounds generated by organic synthesis. The antiviral activity of the drugs was evaluated by their ability to inhibit the replication of SARS-CoV-2 Delta in Vero cell culture. Cytotoxicity of the compounds for this cell line was determined by the MTS assay. Additionally, the ability of the most effective compounds to inhibit iron uptake by Vero cells was assessed using the HMRhoNox-M chemosensor. RESULTS: In the studied stains similar to ferristatin II, direct black (average inhibitory concentration IC50 = 53.7 μM), direct green (IC50 = 53.6 μM), direct diazo black C (IC50 = 28.2 μM), and direct black 2K (IC50 = 45.3 μM) inhibited the viral activity. In addition, direct green showed pronounced toxicity to Vero cells (CC50 = 29.1 μM); whereas none of the black dyes showed cytotoxicity at a highest concentration of 200 μM. The recorded decrease in viral replication in the presence of the drugs correlated with the reduced ability of Vero cells to capture iron, indicating the involvement of TfR1 in the antiviral activity of direct azo stains. CONCLUSION: The study identified general patterns of direct azo dyes that are most active against SARS-CoV-2, i.e. approximately four acidic groups (sulfo groups) at the ends of the molecule and a small rigid flat linker (benzidine) connecting them. The findings open up prospects for the development of safe analogs of ferristatin II. In particular, benzidine may be replaced with less toxic tetramethylbenzidine and diaminoanthraquinone to reduce carcinogenic activity; to improve the structure, we propose to replace the sulfo groups with carboxyl groups.